Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial

JAMA

Volumn 307, Issue 11, 2012, Pages 1169-1177

  Tan, Jianming ^a,b   Wu, Weizhen ^a,b   Xu, Xiumin ^c   Liao, Lianming ^a,b   Zheng, Feng ^a,b   Messinger, Shari ^c   Sun, Xinhui ^a   Chen, Jin ^a,b   Yang, Shunliang ^a   Cai, Jinquan ^a   Gao, Xia ^a   Pileggi, Antonello ^c   Ricordi, Camillo ^c,d  

^a XIAMEN UNIVERSITY   (China)

^b Fujian Key Laboratory of Developmental and Neuro Biology   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD GROUP ABO SYSTEM; CANDIDIASIS; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATURIA; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION RISK; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY PERFUSION; LEUKOPENIA; LIVING DONOR; LOW DRUG DOSE; LYMPHOCELE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; THERAPY EFFECT; URINARY TRACT INFECTION; WOUND HEALING IMPAIRMENT;

EID: 84863338204     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.316     Document Type: Article

References (40)

1. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation. 1994;57(6):857-859. (Pubitemid 24114677)
2. Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with anti-thymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002;2(1):48-56.
3. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28(8):875-884.
4. Hanaway MJ, Woodle ES, Mulgaonkar S, et al INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909-1919.
5. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506. (Pubitemid 350159613)
6. Hoogduijn MJ, Popp FC, Grohnert A, et al MISOT Study Group. Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation. 2010;90(2):124-126.
7. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439-1441. (Pubitemid 38586721)
8. Le Blanc K, Frassoni F, Ball L, et al Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579-1586. (Pubitemid 351626841)
9. Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: data and medical guidelines. Transplantation. 2005;79(6)(suppl):S53-S66.
10. Zhao WY, Zhang L, Han S, et al. Evaluation of living related kidney donors in China: policies and practices in a transplant center. Clin Transplant. 2010;24(5):E158-E162.
11. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. (Pubitemid 44269669)
12. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000;18(2):307-316. (Pubitemid 30056419)
13. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55(2):713-723. (Pubitemid 29082898)
14. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937-2944. (Pubitemid 44484685)
15. Tan J, Qiu J, Lu T, et al. Thirty years of kidney transplantation in two Chinese centers. Clin Transpl. 2005:203-207.
16. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998;66(8):1040-1046. (Pubitemid 28513384)
17. Wynn JJ, Distant DA, Pirsch JD, et al. Kidney and pancreas transplantation. Am J Transplant. 2004;4(Suppl 9):72-80. (Pubitemid 38858996)
18. Chertow GM, Milford EL, Mackenzie HS, Brenner BM. Antigen-independent determinants of cadaveric kidney transplant failure. JAMA. 1996;276(21):1732- 1736. (Pubitemid 26423965)
19. Roodnat JI, Mulder PG, Van Riemsdijk IC, IJzermans JN, van Gelder T, Weimar W. Ischemia times and donor serum creatinine in relation to renal graft failure. Transplantation. 2003;75(6):799-804. (Pubitemid 36373451)
20. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302(10):1067-1075.
21. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010;28(3):585-596.
22. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42-48. (Pubitemid 34059216)
23. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int. 2009;22(4):365-376.
24. Casiraghi F, Noris M, Remuzzi G. Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Curr Opin Organ Transplant. 2010. doi:10.1097/MOT.0b013e328340172c.
25. Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol. 2010;223(1):229-237.
26. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187-1194.
27. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099-1106.
28. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60(6):788-798.
29. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12):1662-1669.
30. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6(2):412-422.
31. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation. 2002;74(4):488-496. (Pubitemid 34977677)
32. Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quiñones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther. 2010;5(4):326-344.
33. Centeno CJ, Schultz JR, Cheever M, et al. Safety and complications reporting update on the reimplantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011;6(4):368-378.
34. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14(6):1035-1041.
35. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol. 2004;15(7):1794-1804. (Pubitemid 38822058)
36. Zhuo W, Liao L, Xu T, Wu W, Yang S, Tan J. Mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal dysfunction by improving the antioxidant/oxidant balance in the ischemic kidney. Urol Int. 2011;86(2):191-196.
37. Kyllönen LE, Salmela KT, Eklund BH, et al. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection. Transpl Int. 2000;13(2):122-128. (Pubitemid 30417367)
38. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311-318. (Pubitemid 34754077)
39. Ekberg H, Tedesco-Silva H, Demirbas A, et al ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-2575. (Pubitemid 350294223)
40. Order of the State Council No. 491. The Regulation on Human Organ Transplantation. 171st Executive Meeting of the State Council. March 21, 2007. http://en.pkulaw.cn/display.aspx?cgid=89844&lib=law. Accessed March 1, 2012.